<DOC>
	<DOCNO>NCT00629499</DOCNO>
	<brief_summary>This non-randomized , Phase II study . Efficacy primary endpoint study ; however , progression-free survival follow determined patient study . Approximately 50 patient plan enrol study .</brief_summary>
	<brief_title>Nanoparticle Albumin-Bound ( Nab ) Paclitaxel/Cyclophosphamide Early-Stage Breast Cancer</brief_title>
	<detailed_description>Given favorable activity demonstrate trial use taxane docetaxel combination cyclophosphamide , propose Phase II trial 4 cycle weekly nab paclitaxel combine cyclophosphamide . The favorable toxicity profile weekly nab paclitaxel , addition demonstrate superiority standard paclitaxel early-stage breast cancer , make ideal taxane evaluate setting . In study , nab paclitaxel administer weekly , combination q3wk cyclophosphamide . By use combination therapy method , goal study maximize opportunity demonstrate improve tolerability adjuvant nab paclitaxel use weekly dosing schedule combination q3wk cyclophosphamide . In study , patient demonstrate FISH IHC3+ HER2 positivity adequate cardiac function also receive treatment trastuzumab addition nab paclitaxel / cyclophosphamide combination therapy . Trastuzumab administer IV use 8 mg/kg load dose Day 1 treatment period . If toxicity occur , subsequent dos trastuzumab administer IV 6 mg/kg dose approximately every 21 day total 52 week ( thus , maintenance therapy trastuzumab continue 12-week period combination therapy nab paclitaxel/cyclophosphamide/trastuzumab end ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm invasive adenocarcinoma breast inflammatory breast cancer , interval definitive breast surgery study registration &lt; 60 day . Definitive surgical treatment must either mastectomy breastconserving therapy axillary lymph node dissection operable breast cancer ( pT1 4 [ include inflammatory breast cancer ] , pN0 3 , M0 ) . Margins resect specimen definitive surgery must histologically free invasive adenocarcinoma ductal carcinoma situ ( DCIS ) . Lobular carcinoma insitu count positive margin . Patients ≥1 axillary lymph node contain metastatic adenocarcinoma measure &gt; 0.2 mm , OR lymph nodenegative patient highrisk feature Patients HER2/neu positive negative tumor ( HER2 positivity must document FISH positivity IHC 3+ ) . Patients receive trastuzumab must normal cardiac function ( MUGA [ cardiac ejection fraction &gt; 50 % , great equal institutional low limit normal ] , echocardiogram [ ECHO ] within institutional normal limit ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) ≤2 . Patients either chemotherapy naïve , receive prior chemotherapy &gt; 5 year ago . Patients previous invasive cancer ( include breast cancer ) eligible treat &gt; 5 year prior enter study , show evidence recurrent disease . Adequate bone marrow function Adequate liver function , Adequate renal function , Patients childbearing potential must use effective method contraception acceptable study physician time signing informed consent least 3 month last dose protocol treatment , must negative pre study serum pregnancy test . Preexisting peripheral neuropathy must less equal grade 1 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) v3.0 criterion . MammoSite® brachytherapy radiation accept perform immediately follow surgery prior receive chemotherapy . Patients bilateral , synchronous breast cancer , provide one primary tumor meet inclusion criterion . Patients pregnant breastfeeding . M1 metastatic disease . Patients require neoadjuvant chemotherapy . Life expectancy great 6 month . History cardiac disease , New York Heart Association ( NYHA ) Class II great CHF Myocardial infarction ( MI ) unstable angina past 12 month prior Day 1 treatment , serious arrhythmia require medication treatment , history stroke transient ischemic attack time , clinically significant peripheral vascular disease , evidence bleed diathesis coagulopathy . Any investigational agent within 30 day receive first dose study drug . Treatment prior trastuzumab bevacizumab therapy . Concurrent treatment anticancer therapy permit . History significant psychiatric disorder . History active , uncontrolled infection . A serious , nonhealing wound , ulcer , bone fracture . Any disease , metabolic dysfunction , finding physical examination , clinical laboratory test result give reasonable suspicion disease condition contraindicate use investigational drug , may affect interpretation result render patient high risk treatment complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Early Stage Breast Cancer</keyword>
	<keyword>Her2-positive</keyword>
	<keyword>nab paclitaxel</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>trastuzumab</keyword>
</DOC>